Autoantibodies	B:C0004358
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
in	O
a	O
distinct	O
subgroup	O
of	O
adult	O
multiple	O
sclerosis	I:C0026769
.	O

Autoantibodies	O
to	O
myelin	B:C0069428
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
in	O
a	O
distinct	O
subgroup	O
of	O
adult	O
multiple	O
sclerosis	I:C0026769
.	O

Autoantibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
in	O
a	O
distinct	O
subgroup	B:C1515021
of	O
adult	O
multiple	O
sclerosis	I:C0026769
.	O

Autoantibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
in	O
a	O
distinct	O
subgroup	O
of	O
adult	O
multiple	B:C0026769
sclerosis	I:C0026769
.	O

To	O
evaluate	B:C0220825
the	O
presence	O
of	O
antibodies	O
to	O
conformation	O
-	O
intact	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
(	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
)	O
in	O
a	O
subgroup	O
of	O
adult	O
patients	O
with	O
clinically	O
definite	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	O
including	O
severe	O
spinal	O
cord	I:C0037925
,	O
optic	O
nerve	I:C0029130
,	O
and	O
brainstem	O
involvement	O
.	O

To	O
evaluate	O
the	O
presence	O
of	O
antibodies	B:C0003241
to	O
conformation	O
-	O
intact	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
(	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
)	O
in	O
a	O
subgroup	O
of	O
adult	O
patients	O
with	O
clinically	O
definite	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	O
including	O
severe	O
spinal	O
cord	I:C0037925
,	O
optic	O
nerve	I:C0029130
,	O
and	O
brainstem	O
involvement	O
.	O

To	O
evaluate	O
the	O
presence	O
of	O
antibodies	O
to	O
conformation	B:C0033625
-	O
intact	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
(	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
)	O
in	O
a	O
subgroup	O
of	O
adult	O
patients	O
with	O
clinically	O
definite	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	O
including	O
severe	O
spinal	O
cord	I:C0037925
,	O
optic	O
nerve	I:C0029130
,	O
and	O
brainstem	O
involvement	O
.	O

To	O
evaluate	O
the	O
presence	O
of	O
antibodies	O
to	O
conformation	O
-	O
intact	O
myelin	B:C0069428
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
(	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
)	O
in	O
a	O
subgroup	O
of	O
adult	O
patients	O
with	O
clinically	O
definite	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	O
including	O
severe	O
spinal	O
cord	I:C0037925
,	O
optic	O
nerve	I:C0029130
,	O
and	O
brainstem	O
involvement	O
.	O

To	O
evaluate	O
the	O
presence	O
of	O
antibodies	O
to	O
conformation	O
-	O
intact	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
(	O
myelin	B:C0069428
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
)	O
in	O
a	O
subgroup	O
of	O
adult	O
patients	O
with	O
clinically	O
definite	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	O
including	O
severe	O
spinal	O
cord	I:C0037925
,	O
optic	O
nerve	I:C0029130
,	O
and	O
brainstem	O
involvement	O
.	O

To	O
evaluate	O
the	O
presence	O
of	O
antibodies	O
to	O
conformation	O
-	O
intact	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
(	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
)	O
in	O
a	O
subgroup	B:C1515021
of	O
adult	O
patients	O
with	O
clinically	O
definite	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	O
including	O
severe	O
spinal	O
cord	I:C0037925
,	O
optic	O
nerve	I:C0029130
,	O
and	O
brainstem	O
involvement	O
.	O

To	O
evaluate	O
the	O
presence	O
of	O
antibodies	O
to	O
conformation	O
-	O
intact	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
(	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
)	O
in	O
a	O
subgroup	O
of	O
adult	O
patients	O
with	O
clinically	O
definite	O
multiple	B:C0026769
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	O
including	O
severe	O
spinal	O
cord	I:C0037925
,	O
optic	O
nerve	I:C0029130
,	O
and	O
brainstem	O
involvement	O
.	O

To	O
evaluate	O
the	O
presence	O
of	O
antibodies	O
to	O
conformation	O
-	O
intact	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
(	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
)	O
in	O
a	O
subgroup	O
of	O
adult	O
patients	O
with	O
clinically	O
definite	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	B:C0026769
sclerosis	I:C0026769
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	O
including	O
severe	O
spinal	O
cord	I:C0037925
,	O
optic	O
nerve	I:C0029130
,	O
and	O
brainstem	O
involvement	O
.	O

To	O
evaluate	O
the	O
presence	O
of	O
antibodies	O
to	O
conformation	O
-	O
intact	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
(	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
)	O
in	O
a	O
subgroup	O
of	O
adult	O
patients	O
with	O
clinically	O
definite	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	O
including	O
severe	O
spinal	B:C0037925
cord	I:C0037925
,	O
optic	O
nerve	I:C0029130
,	O
and	O
brainstem	O
involvement	O
.	O

To	O
evaluate	O
the	O
presence	O
of	O
antibodies	O
to	O
conformation	O
-	O
intact	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
(	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
)	O
in	O
a	O
subgroup	O
of	O
adult	O
patients	O
with	O
clinically	O
definite	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	O
including	O
severe	O
spinal	O
cord	I:C0037925
,	O
optic	B:C0029130
nerve	I:C0029130
,	O
and	O
brainstem	O
involvement	O
.	O

To	O
evaluate	O
the	O
presence	O
of	O
antibodies	O
to	O
conformation	O
-	O
intact	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
(	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
)	O
in	O
a	O
subgroup	O
of	O
adult	O
patients	O
with	O
clinically	O
definite	O
multiple	O
sclerosis	I:C0026769
(	O
multiple	O
sclerosis	I:C0026769
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	O
including	O
severe	O
spinal	O
cord	I:C0037925
,	O
optic	O
nerve	I:C0029130
,	O
and	O
brainstem	B:C0006121
involvement	O
.	O

Antibodies	B:C0003241
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	O
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	O
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	O
diseases	I:C0011303
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
multiple	O
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	O
type	I:C0026769
II	I:C0026769
(	O
group	O
3	I:C1257890
)	O
.	O

Antibodies	O
to	O
myelin	B:C0069428
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	O
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	O
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	O
diseases	I:C0011303
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
multiple	O
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	O
type	I:C0026769
II	I:C0026769
(	O
group	O
3	I:C1257890
)	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	B:C0005507
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	O
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	O
diseases	I:C0011303
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
multiple	O
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	O
type	I:C0026769
II	I:C0026769
(	O
group	O
3	I:C1257890
)	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	O
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	B:C1257890
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	O
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	O
diseases	I:C0011303
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
multiple	O
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	O
type	I:C0026769
II	I:C0026769
(	O
group	O
3	I:C1257890
)	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	O
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	B:C0026769
sclerosis	I:C0026769
(	O
group	O
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	O
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	O
diseases	I:C0011303
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
multiple	O
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	O
type	I:C0026769
II	I:C0026769
(	O
group	O
3	I:C1257890
)	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	O
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	B:C1257890
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	O
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	O
diseases	I:C0011303
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
multiple	O
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	O
type	I:C0026769
II	I:C0026769
(	O
group	O
3	I:C1257890
)	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	O
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	B:C0026769
sclerosis	I:C0026769
(	O
group	O
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	O
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	O
diseases	I:C0011303
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
multiple	O
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	O
type	I:C0026769
II	I:C0026769
(	O
group	O
3	I:C1257890
)	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	O
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	B:C1257890
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	O
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	O
diseases	I:C0011303
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
multiple	O
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	O
type	I:C0026769
II	I:C0026769
(	O
group	O
3	I:C1257890
)	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	O
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	B:C0740294
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	O
diseases	I:C0011303
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
multiple	O
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	O
type	I:C0026769
II	I:C0026769
(	O
group	O
3	I:C1257890
)	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	O
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	O
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	B:C0011303
diseases	I:C0011303
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
multiple	O
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	O
type	I:C0026769
II	I:C0026769
(	O
group	O
3	I:C1257890
)	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	O
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	O
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	O
diseases	I:C0011303
of	O
the	O
CNS	B:C3714787
(	O
n	O
=	O
19	O
with	O
multiple	O
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	O
type	I:C0026769
II	I:C0026769
(	O
group	O
3	I:C1257890
)	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	O
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	O
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	O
diseases	I:C0011303
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
multiple	B:C0026769
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	O
type	I:C0026769
II	I:C0026769
(	O
group	O
3	I:C1257890
)	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	O
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	O
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	O
diseases	I:C0011303
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
multiple	O
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	B:C0008902
as	O
MS	O
type	I:C0026769
II	I:C0026769
(	O
group	O
3	I:C1257890
)	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	O
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	O
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	O
diseases	I:C0011303
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
multiple	O
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	B:C0026769
type	I:C0026769
II	I:C0026769
(	O
group	O
3	I:C1257890
)	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
investigated	O
using	O
a	O
cell	O
-	I:C0005507
based	I:C0005507
assay	I:C0005507
in	O
3	O
groups	O
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
1	I:C1257890
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
(	O
group	O
2	I:C1257890
)	O
,	O
and	O
in	O
22	O
brain	O
-	I:C0740294
biopsied	I:C0740294
patients	O
with	O
demyelinating	O
diseases	I:C0011303
of	O
the	O
CNS	O
(	O
n	O
=	O
19	O
with	O
multiple	O
sclerosis	I:C0026769
)	O
,	O
4	O
of	O
whom	O
classified	O
as	O
MS	O
type	I:C0026769
II	I:C0026769
(	O
group	B:C1257890
3	I:C1257890
)	O
.	O

Recognized	O
epitopes	B:C0003316
were	O
identified	O
with	O
mutated	O
variants	O
of	O
myelin	O
oligodendrocyte	I:C1417228
glycoprotein	I:C1417228
.	O

Recognized	O
epitopes	O
were	O
identified	O
with	O
mutated	B:C0596611
variants	O
of	O
myelin	O
oligodendrocyte	I:C1417228
glycoprotein	I:C1417228
.	O

Recognized	O
epitopes	O
were	O
identified	O
with	O
mutated	O
variants	B:C0678941
of	O
myelin	O
oligodendrocyte	I:C1417228
glycoprotein	I:C1417228
.	O

Recognized	O
epitopes	O
were	O
identified	O
with	O
mutated	O
variants	O
of	O
myelin	B:C1417228
oligodendrocyte	I:C1417228
glycoprotein	I:C1417228
.	O

Antibodies	B:C0003241
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
found	O
in	O
about	O
5	O
%	O
(	O
5/104	O
)	O
of	O
preselected	O
adult	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
.	O

Antibodies	O
to	O
myelin	B:C0069428
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
found	O
in	O
about	O
5	O
%	O
(	O
5/104	O
)	O
of	O
preselected	O
adult	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
were	O
found	O
in	O
about	O
5	O
%	O
(	O
5/104	O
)	O
of	O
preselected	O
adult	O
patients	O
with	O
multiple	B:C0026769
sclerosis	I:C0026769
.	O

In	O
contrast	O
,	O
in	O
groups	B:C1257890
2	I:C1257890
and	O
3	O
,	O
none	O
of	O
the	O
patients	O
tested	O
positive	O
for	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
antibodies	O
.	O

In	O
contrast	O
,	O
in	O
groups	O
2	I:C1257890
and	O
3	B:C1257890
,	O
none	O
of	O
the	O
patients	O
tested	O
positive	O
for	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
antibodies	O
.	O

In	O
contrast	O
,	O
in	O
groups	O
2	I:C1257890
and	O
3	O
,	O
none	O
of	O
the	O
patients	O
tested	O
positive	O
for	O
myelin	B:C0069428
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
antibodies	O
.	O

In	O
contrast	O
,	O
in	O
groups	O
2	I:C1257890
and	O
3	O
,	O
none	O
of	O
the	O
patients	O
tested	O
positive	O
for	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
antibodies	B:C0003241
.	O

Patients	O
with	O
multiple	B:C0026769
sclerosis	I:C0026769
with	O
antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
predominantly	O
manifested	O
with	O
concomitant	O
severe	O
brainstem	O
and	O
spinal	O
cord	I:C0037925
involvement	O
and	O
had	O
a	O
severe	O
disease	O
course	I:C0242656
with	O
high	O
relapse	O
rates	O
and	O
failure	O
to	O
several	O
disease	O
-	I:C0087111
modifying	I:C0087111
therapies	I:C0087111
.	O

Patients	O
with	O
multiple	O
sclerosis	I:C0026769
with	O
antibodies	B:C0003241
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
predominantly	O
manifested	O
with	O
concomitant	O
severe	O
brainstem	O
and	O
spinal	O
cord	I:C0037925
involvement	O
and	O
had	O
a	O
severe	O
disease	O
course	I:C0242656
with	O
high	O
relapse	O
rates	O
and	O
failure	O
to	O
several	O
disease	O
-	I:C0087111
modifying	I:C0087111
therapies	I:C0087111
.	O

Patients	O
with	O
multiple	O
sclerosis	I:C0026769
with	O
antibodies	O
to	O
myelin	B:C0069428
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
predominantly	O
manifested	O
with	O
concomitant	O
severe	O
brainstem	O
and	O
spinal	O
cord	I:C0037925
involvement	O
and	O
had	O
a	O
severe	O
disease	O
course	I:C0242656
with	O
high	O
relapse	O
rates	O
and	O
failure	O
to	O
several	O
disease	O
-	I:C0087111
modifying	I:C0087111
therapies	I:C0087111
.	O

Patients	O
with	O
multiple	O
sclerosis	I:C0026769
with	O
antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
predominantly	O
manifested	O
with	O
concomitant	O
severe	O
brainstem	B:C0006121
and	O
spinal	O
cord	I:C0037925
involvement	O
and	O
had	O
a	O
severe	O
disease	O
course	I:C0242656
with	O
high	O
relapse	O
rates	O
and	O
failure	O
to	O
several	O
disease	O
-	I:C0087111
modifying	I:C0087111
therapies	I:C0087111
.	O

Patients	O
with	O
multiple	O
sclerosis	I:C0026769
with	O
antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
predominantly	O
manifested	O
with	O
concomitant	O
severe	O
brainstem	O
and	O
spinal	B:C0037925
cord	I:C0037925
involvement	O
and	O
had	O
a	O
severe	O
disease	O
course	I:C0242656
with	O
high	O
relapse	O
rates	O
and	O
failure	O
to	O
several	O
disease	O
-	I:C0087111
modifying	I:C0087111
therapies	I:C0087111
.	O

Patients	O
with	O
multiple	O
sclerosis	I:C0026769
with	O
antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
predominantly	O
manifested	O
with	O
concomitant	O
severe	O
brainstem	O
and	O
spinal	O
cord	I:C0037925
involvement	O
and	O
had	O
a	O
severe	O
disease	B:C0242656
course	I:C0242656
with	O
high	O
relapse	O
rates	O
and	O
failure	O
to	O
several	O
disease	O
-	I:C0087111
modifying	I:C0087111
therapies	I:C0087111
.	O

Patients	O
with	O
multiple	O
sclerosis	I:C0026769
with	O
antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
predominantly	O
manifested	O
with	O
concomitant	O
severe	O
brainstem	O
and	O
spinal	O
cord	I:C0037925
involvement	O
and	O
had	O
a	O
severe	O
disease	O
course	I:C0242656
with	O
high	O
relapse	O
rates	O
and	O
failure	B:C0162643
to	O
several	O
disease	O
-	I:C0087111
modifying	I:C0087111
therapies	I:C0087111
.	O

Patients	O
with	O
multiple	O
sclerosis	I:C0026769
with	O
antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
predominantly	O
manifested	O
with	O
concomitant	O
severe	O
brainstem	O
and	O
spinal	O
cord	I:C0037925
involvement	O
and	O
had	O
a	O
severe	O
disease	O
course	I:C0242656
with	O
high	O
relapse	O
rates	O
and	O
failure	O
to	O
several	O
disease	B:C0087111
-	I:C0087111
modifying	I:C0087111
therapies	I:C0087111
.	O

Three	O
of	O
them	O
had	O
been	O
treated	B:C0332293
with	I:C0332293
plasma	O
exchange	I:C0032113
with	O
a	O
favorable	O
response	O
.	O

Three	O
of	O
them	O
had	O
been	O
treated	O
with	I:C0332293
plasma	B:C0032113
exchange	I:C0032113
with	O
a	O
favorable	O
response	O
.	O

All	O
anti-MOG	B:C1291777
-	O
positive	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
showed	O
typical	O
multiple	O
sclerosis	I:C0026769
lesions	O
on	O
brain	O
MRI	I:C0412675
.	O

All	O
anti-MOG	O
-	O
positive	O
patients	O
with	O
multiple	B:C0026769
sclerosis	I:C0026769
showed	O
typical	O
multiple	O
sclerosis	I:C0026769
lesions	O
on	O
brain	O
MRI	I:C0412675
.	O

All	O
anti-MOG	O
-	O
positive	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
showed	O
typical	O
multiple	B:C0026769
sclerosis	I:C0026769
lesions	O
on	O
brain	O
MRI	I:C0412675
.	O

All	O
anti-MOG	O
-	O
positive	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
showed	O
typical	O
multiple	O
sclerosis	I:C0026769
lesions	B:C0221198
on	O
brain	O
MRI	I:C0412675
.	O

All	O
anti-MOG	O
-	O
positive	O
patients	O
with	O
multiple	O
sclerosis	I:C0026769
showed	O
typical	O
multiple	O
sclerosis	I:C0026769
lesions	O
on	O
brain	B:C0412675
MRI	I:C0412675
.	O

Longitudinal	O
analysis	O
up	O
to	O
9	O
years	O
revealed	O
fluctuations	B:C0231239
and	O
reappearance	O
of	O
anti-MOG	O
reactivity	I:C1621287
.	O

Longitudinal	O
analysis	O
up	O
to	O
9	O
years	O
revealed	O
fluctuations	O
and	O
reappearance	O
of	O
anti-MOG	B:C1621287
reactivity	I:C1621287
.	O

Epitope	B:C0242831
mapping	I:C0242831
indicated	O
interindividual	O
heterogeneity	O
,	O
yet	O
intraindividual	O
stability	O
of	O
the	O
antibody	O
response	I:C0003261
.	O

Epitope	O
mapping	I:C0242831
indicated	O
interindividual	O
heterogeneity	O
,	O
yet	O
intraindividual	O
stability	O
of	O
the	O
antibody	B:C0003261
response	I:C0003261
.	O

Antibodies	B:C0003241
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
can	O
be	O
found	O
in	O
a	O
distinct	O
subgroup	O
of	O
adult	O
multiple	O
sclerosis	I:C0026769
with	O
a	O
specific	O
clinical	O
phenotype	O
and	O
may	O
indicate	O
disease	O
heterogeneity	O
.	O

Antibodies	O
to	O
myelin	B:C0069428
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
can	O
be	O
found	O
in	O
a	O
distinct	O
subgroup	O
of	O
adult	O
multiple	O
sclerosis	I:C0026769
with	O
a	O
specific	O
clinical	O
phenotype	O
and	O
may	O
indicate	O
disease	O
heterogeneity	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
can	O
be	O
found	O
in	O
a	O
distinct	O
subgroup	B:C1515021
of	O
adult	O
multiple	O
sclerosis	I:C0026769
with	O
a	O
specific	O
clinical	O
phenotype	O
and	O
may	O
indicate	O
disease	O
heterogeneity	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
can	O
be	O
found	O
in	O
a	O
distinct	O
subgroup	O
of	O
adult	O
multiple	B:C0026769
sclerosis	I:C0026769
with	O
a	O
specific	O
clinical	O
phenotype	O
and	O
may	O
indicate	O
disease	O
heterogeneity	O
.	O

Antibodies	O
to	O
myelin	O
oligodendrocyte	I:C0069428
glycoprotein	I:C0069428
can	O
be	O
found	O
in	O
a	O
distinct	O
subgroup	O
of	O
adult	O
multiple	O
sclerosis	I:C0026769
with	O
a	O
specific	O
clinical	O
phenotype	O
and	O
may	O
indicate	O
disease	B:C0012634
heterogeneity	O
.	O

